Natural killer cell cytotoxicity is a predictor of outcome for patients with high risk myelodysplastic syndrome and oligoblastic acute myeloid leukemia treated with azacytidine-Reference-Cited by-同舟云学术

Natural killer cell cytotoxicity is a predictor of outcome for patients with high risk myelodysplastic syndrome and oligoblastic acute myeloid leukemia treated with azacytidine

Published:2019-04-05 Issue:10 Volume:60 Page:2457-2463
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Tsirogianni Maria¹,Grigoriou Eirini²,Kapsimalli Violetta³,Dagla Kleopatra⁴,Stamouli Maria⁴,Gkirkas Konstantinos⁴,Konsta Eve⁴,Karagiannidou Angeliki⁴,Gkodopoulos Konstantinos⁴,Stavroulaki Georgia⁴,Pappa Vassiliki⁴,Angelopoulou Maria⁵,Lowdell Mark⁶,Tsirigotis Panagiotis⁴

Affiliation:

1. Department of Hematology and Bone Marrow Transplantation, Saint Savvas Regional Cancer Hospital, Athens, Greece;

2. Department of Immunology and Histocompatibility, “Evangelismos” General Hospital, Athens, Greece;

3. Department of Microbiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece;

4. Hematology Division, 2nd Department of Internal Medicine, “ATTIKO” General University Hospital, National and Kapodistrian University of Athens, Athens, Greece;

5. Department of Hematology and Bone Marrow Transplantation, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece;

6. Institute of Immunity and Transplantation Centre for Cell, Gene & Tissue Therapeutics, Royal Free Hospital, London, UK

Funder

Janssen Hellas

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2019.1581935

Reference20 articles.

1. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study